The growing interest in peptide therapies is colliding with an increasingly complex and evolving regulatory landscape. Federal regulators are taking steps to more clearly define how peptides can be developed, marketed, and compounded, with the U.S. Food and Drug Administration (FDA) expected to play a central role in determining which substances may be eligible for compounding and under what conditions. While there is momentum to expand access, the path forward will involve formal rulemaking, scientific review, and heightened scrutiny over sourcing, safety, and marketing claims, creating both opportunity and uncertainty for industry stakeholders.
In an article featured in Law360, Jesse Dresser emphasized that any regulatory shift will be deliberate and far from immediate. As he noted, FDA action on peptides is “just a ‘first procedural step’ toward formal action.” Companies should prepare for a structured rulemaking environment, increased oversight, and continued compliance obligations as the agency works to establish a sustainable regulatory framework.
Read the full article with Law360 (subscription required).
